fluorouracil and Headache

fluorouracil has been researched along with Headache in 10 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.

Research

Studies (10)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Percentage of Participants Who Completed ≥ 95% of the Planned Radiotherapy Treatment With Concurrent Trastuzumab Emtansine Administration Without Significant (> 5 Days) Delay

(NCT01196052)
Timeframe: From the start to the end of radiotherapy treatment (up to 51 weeks)

Percentage of Participants Who Completed the Planned Duration of Trastuzumab Emtansine Treatment

Participants were to receive up to a total of 17 cycles of trastuzumab emtansine. If trastuzumab was given concurrently with either the optional docetaxel or optional radiation, then the number of 3-week cycles of trastuzumab therapy was subtracted from the planned 17 cycles of trastuzumab emtansine therapy. (NCT01196052)
Timeframe: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)

Percentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Hormonal Therapy With Trastuzumab Emtansine Treatment

(NCT01196052)
Timeframe: From the start to the end of concurrent hormonal therapy (up to 51 weeks)

Percentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Radiotherapy With Trastuzumab Emtansine Treatment

(NCT01196052)
Timeframe: From the start to the end of concurrent radiotherapy (up to 51 weeks)

Percentage of Participants With a Cardiac Event Within 12 Weeks After the Start of Trastuzumab Emtansine Treatment

A cardiac event was defined as death from a cardiac cause or severe congestive failure (New York Heart Association [NYHA] Class III or IV) with a decrease in left ventricular ejection fraction (LVEF) of ≥ 10% from Baseline to an LVEF of < 50%. (NCT01196052)
Timeframe: Baseline to 12 weeks after the start of trastuzumab emtansine treatment

Percentage of Participants With a Pathological Complete Response

Pathological complete response was defined as the absence of invasive neoplastic cells at microscopic examination of the primary tumor and lymph nodes after surgery following primary systemic therapy. Pathological complete response was evaluated in participants treated with neoadjuvant therapy doxorubicin/cyclophosphamide-5-fluorouracil/epirubicin/cyclophosphamide followed by 1 or more doses of trastuzumab emtansine and who underwent surgery. (NCT01196052)
Timeframe: Day of surgery

Adverse Events, LVEF Function, and Deaths

The following percentages of participants are reported: At least 1 adverse event while receiving T-DM1; at least 1 serious adverse event while receiving T-DM1; an adverse event leading to discontinuation, dose delay, or dose reduction of trastuzumab emtansine treatment; symptomatic cardiac dysfunction; and asymptomatic decline in left ventricular ejection fraction (LVEF). An asymptomatic LVEF decline was defined as a LVEF < 50% and a maximum decrease ≥ 10% from Baseline. The percentage of participants who died is reported. (NCT01196052)
Timeframe: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)

Trials

4 trials available for fluorouracil and Headache

Other Studies

6 other studies available for fluorouracil and Headache